An observation:
Look at the IMMU one-year chart. June 2, 2016 peak was 5.30, and Feb. 17, 2017 share price is 5.34. Between those two peaks is doubt: management, the ASCO fiasco, etc.--a great opportunity for investors, preying on uncertainty. What has pushed the share price higher is more data, confirming the data before the first peak. Which means, by logical conclusion, another, higher, peak will rise, towering over an eoy chart like Everest. (Actually, that "logical conclusion" part, it was a joke; in biotech, there is no such thing.)
